Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel, doxorubicin, and cyclophosphamide in treating women who have previously untreated stage III breast cancer.

Key facts

Study ID

NCT00004175

Run by

Northwestern University

Starts

1998-11-01

Expected to finish

2005-06-01

Last updated by the study team

2012-06-06

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Stanford University Medical Center — Stanford, California, United States
• Monroe Medical Associates — Chicago, Illinois, United States
• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States
• Albert Einstein Comprehensive Cancer Center — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.